Contrave

Description

Contrave (bupropion-naltrexone) is a prescription medication used to aid weight loss in adults with obesity. Developed by the U.S. pharmaceutical company Takeda Pharmaceutical Company, Contrave was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of chronic weight management, combined with a reduced-calorie diet and increased physical activity. It is designed for adults with obesity (body mass index (BMI) >30) or overweight (BMI >27) with one obesity-related condition such as type 2 diabetes, cardiovascular disease, hypertension, or high cholesterol.

its a combination of two drugs, naltrexone and bupropion, both of which have a long history of successful use for problems besides obesity.  Naltraxone was first approved by the FDA in 1984, and is used to treat alcohol use disorder and opioid dependence by reducing the cravings for these substances. Similarly, naltraxone reduces the cravings for food that occur during a weight loss program.